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1. Introduction 
Trabeculectomy is the most commonly used surgical procedure for managing medically 
uncontrolled glaucoma. It reduces intraocular pressure (IOP) by creating an artificial drainage 
pathway of the aqueous humor from the anterior chamber to the subconjunctival space, 
forming a filtering bleb. Aqueous humor in the subconjunctival space may then exit by 
multiple pathways including transconjunctival filtration and absorption through the 
episcleral veins (Fig. 1).  
 
 
Fig. 1. Aqueous pathway after trabeculectomy through peripheral iridectomy (1) to the 
anterior chamber (2), the internal ostium (3), the route under the scleral flap (4), and the edge 
of the scleral flap to be absorbed via the bleb wall (5), and the episcleral venous plexus (6) 
The success of trabeculectomy has been limited by postoperative fibrosis at the surgery site, 
leading to bleb failure months or years after surgery. High risk factors that lead to the failure 
in trabeculectomy include previous ocular surgery, specific types of glaucoma e.g. secondary 
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glaucoma such as neovascular, uveitic, post-traumatic, and lens-induced glaucoma, and to a 
lesser extent, young age and black race (Sturmer et al, 1993; Broadway and Chang, 2001). 
Several surgical and pharmacologic techniques have been introduced to enhance the success 
in eyes with poor surgical prognoses. Until now, no effective and safe agent has been 
identified that can inhibit fibrosis, without complications, in the glaucoma filtering wound 
created by trabeculectomy. Although antimetabolites have revolutionized glaucoma surgery, 
the use of these agents is still associated with substantial risk (Chen, 1983).  The common 
clinical practice of using mitomycin C (MMC) in trabeculectomy as an anti-fibrotic and anti-
metabolic agent has achieved only limited success in cases with high-risk glaucoma while 
raising notable sight-threatening complications such as hypotony, bleb leaks, and infection 
(Lama and Fechtner, 2003).  
To circumvent complications caused by MMC, there is a great need to improve the outcome 
of trabeculectomy by identifying a physiological modulator that may suppress pathological 
fibrosis without compromising the normal reparative wound healing process. 
Our recent clinical research suggests that amniotic membrane (AM) could be a physiological 
modulator of wound healing that prevents scar formation in the subconjunctival space. We 
have demonstrated that AM not only prevents scar formation via its anti-inflammatory and 
anti-scarring actions but also serves as a spacer integrated into the intra-bleb structure to 
avert early over-filtration complications associated with trabeculectomy, and to stabilize the 
patency of the filtering fistula for prolonged maintenance of the bleb function (Sheha et al, 
2008). This chapter reviews recent advances in the use of amniotic membrane as a biological 
modulator of wound healing that suppresses pathological fibrosis in trabeculectomy. 
2. Wound healing process following trabeculectomy  
Wound healing is triggered by activating the body’s innate immunity and is characterized 
by inflammation in the acute phase, granulation tissue formation in the intermediate phase, 
and scarring in the chronic phase. This wound healing process is mediated by a number of 
cell types and is orchestrated by complex arrays of growth factors, cytokines, chemokines, 
and non-protein mediators. Trabeculectomy differs from most surgical procedures in that 
inhibition of wound healing is desirable to achieve surgical success (Dvorak, 1986).  
Experimental and human studies have outlined a sequence of events that occurs in early 
bleb failure (Summarized in Fig. 2) (Skuta and Parrish, 1987). After surgical trauma, plasma 
proteins, including fibrinogen, fibronectin, and plasminogen, form a gel-like fibrin-
fibronectin matrix, into which inflammatory cells (including monocytes and macrophages), 
new capillaries, and fibroblasts migrate. Macrophages from monocytes appear in about 12 
hours, reaching peak numbers around day 3. These macrophages activate an inflammatory 
response, including the activation of lymphocytes and fibroblasts. T-cells appear on day 5, 
and after reaching a peak in numbers by the end of two weeks, they are activated into 
specific T-cells, which release various cytokines to control the activity and proliferation of 
fibroblasts. The fibrin-fibronectin matrix is eventually degraded by inflammatory cells, and 
fibroblasts subsequently synthesize fibronectin, interstitial collagens, and glycosaminoglycans 
to form fibrovascular granulation tissue (Desjardins et al, 1986; Grierson et al, 1988; Reichel 
et al, 1998; Miller et al, 1989; Chang et al, 2000). 
The proliferated fibroblasts gradually begin to differentiate; this process is suspected to be 
mediated by various factors: transforming growth factor (TGF)-beta (Wipff et al, 2007), 
connective-tissue growth factor (CTGF) (Sherwood, 2006), Rho-associated serine-threonine 
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kinase (ROCK1) (Meyer-ter-Vehn et al, 2006), and the matrix-metalloproteinases (MMPs) 
(Chintala et al, 2005). Unlike undifferentiated fibroblasts, the newly-differentiated 
myofibroblasts transform the secreted extracellular matrix into an actin-based component 
which creates stronger scar tissue (Desmouliere et al, 1993). Blood vessels retract over time 
and fibroblasts largely disappear as the tissue is remodeled to form a dense collagenous 
subconjunctival scar.  
 
Trabeculectomy 
Release of Plasma Proteins & Blood Cells 
Dense Collagenous Subconjunctival Scar 
Tissue Factor(s) 
Formation of Fibrin - Fibronectin Clot/Matrix 
 
Immigration and Replication of Macrophages, 
 Fibroblasts, and New Capillaries 
 
Fibroblasts Synthesis of Collagen, 
Glycosaminoglycans, and Fibronectin 
Formation of Fibrovascular Granulation Tissue 
 
Continued Collagen Synthesis, Capillary 
resorption, Disappearance of Fibroblasts 
 
Fig. 2. Events of wound healing in trabeculectomy failure 
3. Risk factors and potential causes of trabeculectomy failure 
3.1 External factors 
External factors at the episceral-conjunctival interface are responsible for most cases of 
trabeculectomy failure. Fibroblast proliferation, synthesis of the extracellular matrix, and 
subsequent development of subconjunctival fibrosis play prominent roles in external failure.  
Chemotactic factors for fibroblasts include lymphokines, complement, native collagens of 
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types I to V, fibronectin, some proteolytic digestion fragments of collagen and fibronectin, 
and platelet-derived growth factor (Ross et al, 1986). 
Intense preoperative and postoperative inflammation induces a cellular response that 
accelerates wound healing. The presence of blood beneath the conjunctiva may also increase 
the probability of bleb failure. As noted above, serum derivatives including fibronectin and 
platelet-derived growth factor may stimulate fibroblast migration and proliferation. In 
addition, macrophages, which may be activated by blood, appear to play a key role in 
inducing the fibroproliferative response in wound repair (Leibovich and Ross, 1975). 
Extrapolation of these observations to trabeculectomy wound healing is consistent with the 
clinical impression that the presence of blood increases the likelihood of postoperative 
fibrosis. 
3.2 Intraocular factors 
In the absence of scar formation, an inadequate opening into the anterior chamber due to 
scleral remnants or Descemet’s membrane in the fistula may lead to primary failure. 
Blockage of the filtration site by prolapsed iris, vitreous, or ciliary body may also lead to 
early postoperative failure (Maumenee, 1960).  Many of these potential causes of bleb failure 
can be avoided by careful surgical technique. A spacer during surgery can enhance the 
likelihood of a patent fistula.  
4. Measures to improve the trabeculectomy outcome 
Trabeculectomy success relies on the continued patency of the fistula and the continued 
ability of the filtering bleb created out of the conjunctiva to absorb aqueous humor. Thus, 
the success of the procedure lies not only on the surgical technique but also the 
intraoperative and postoperative measures to minimize scar formation. 
Preoperative inflammation should be treated with anti-inflammatory agents, usually 
corticosteroids. Miotics, which break down the blood-aqueous barrier, should be 
discontinued at least two weeks before trabeculectomy. Treatment of postoperative 
inflammation is also important. Cycloplegic agents help restore the blood-aqueous barrier 
and may reduce the release of plasma proteins, which may contribute to the postoperative 
healing response. 
With respect to surgical technique, tissue trauma should be minimized by avoiding 
unnecessary manipulation of the conjunctiva, Tenon and iris. Hemostasis should be 
performed to decrease bleeding. Removal of the inner sclerectomy block should establish a 
patent channel without remnants of Descemet’s membrane. A basal iridectomy prevents 
postoperative iris incarceration at the filtering site.  
Although a fornix-based conjunctival flap might prevent scarring of the posterior 
conjunctiva and Tenon’s capsule, randomized studies of limbus versus fornix-based 
conjunctival flaps in primary trabeculectomies failed to document significant differences in 
surgical success between the two techniques (Shuster et al, 1984; Traverso et al, 1987). The 
effect of the excision of Tenon’s capsule on trabeculectomy success is also controversial. 
5. Pharmacologic modulation of wound healing 
Unlike most surgical procedures, success of glaucoma filtering surgery is achieved through 
the inhibition of wound healing. The use of pharmacologic agents is based on suppression 
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of proliferation of cells, mainly fibroblasts, which would limit the healing at the site of the 
fistulizing surgery and consequently limit postoperative scarring.   
5.1 Corticosteroids 
As stated above, the initial steps in wound healing are inflammation and coagulation, 
leading to a cascade of biological events including cellular, hormonal, and growth factor 
release. These events finally lead to scar tissue formation (Skuta and Parrish, 1987). 
Corticosteroids regulate wound healing through the inhibition of macrophage functions, 
such as phagocytosis and the release of enzymes like collagenase, plasminogen activator, 
and growth factors, and thus suppress inflammation. Specific anti-inflammatory effects 
include suppression of fibrin deposition, capillary permeability, migration of leukocytes and 
macrophages, and phagocytic activity (Starita et al, 1985). Corticosteroids also inhibit 
vascular permeability and fibroblast proliferation (Lama and Fechtner, 2003). Tissue culture 
studies of human Tenon capsule fibroblasts have shown that corticosteroids inhibit cell 
attachment and proliferation (Nguyen and Lee, 1992). 
Postoperative topical corticosteroids have been reported to significantly increase the success 
of trabeculectomy (Araujo 1995).  Sub-Tenon injection of triamcinolone acetonide (TA) 
appears to be a more effective mean of high-dose corticosteroid delivery and may increase 
the success rate of trabeculectomy (Hosseini 2007). Tham and associates reported that the 
use of TA (1.2 mg) injection into filtration blebs at the conclusion of trabeculectomy was 
associated with good intraocular pressure (IOP) control for 3 months (Tham 2006). 
However, Yuki et al reported no significant differences between the success rates of 
trabeculectomy with or without intraoperative sub-Tenon injection of 20 mg TA within the 
12-month follow-up period (Yuki, 2009).  
Besides intra- and post-operative administration, some studies have highlighted the 
beneficial effect of preoperative use of corticosteroids and non steroidal anti-inflammatory 
agents in improving the success rate of filtration surgery. Baudouin demonstrated that 
fluorometholone drops one month before filtering surgery has effectively reduced 
inflammation, as indicated by the expression of human leukocyte antigen (HLA)-DR after 
impression cytological analysis (Baudouin 2002). Breusegem compared preoperative topical 
anti-inflammatory medications to placebo before trabeculectomy. Significantly fewer 
postoperative needling procedures were needed in the steroid-treated group (5%) than in 
the placebo group (41%). Furthermore, none of the patients in the steroid group required 
topical IOP-lowering medication to maintain a subtarget IOP, compared with 24% of 
patients in the placebo group. However, there was no significant overall difference in 
absolute IOP values or in relative IOP reduction between two groups at any point 
(Breusegem 2010). Despite the aforementioned advantages, topical steroids pose a risk for 
steroid-induced IOP elevation and cataract.  
5.2 Antimetabolites  
Anti-mitotic agents such as MMC and 5-fluorouracil (5-FU) help suppress post-surgical 
scarring by causing widespread non-selective cell death and apoptosis. The intraoperative 
application of MMC in trabeculectomy was introduced by Chen (Chen, 1983), while Heuer 
was the first to report the use 5-FU postoperatively as subconjunctival injections (Heuer et 
al, 1984).   
While 5-FU can be used both for intraoperative application and postoperative injection 
(Parrish et al, 2001), the use of MMC as a postoperative injection is not as widely accepted as 
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5-FU (Apostolov and Siarov, 1996). The concentration of 5-FU used intraoperatively is 50 
mg/mL applied for up to 5 minutes. The concentration of MMC used intraoperatively 
ranges from 0.1-0.5 mg/mL applied for 2-5 minutes, depending on the risk of failure. The 
antifibrotic agent can be applied to the scleral bed before or after the scleral flap is made, 
using cellulose sponges. The antifibrotic-soaked sponges should be applied to the area 
where aqueous flow is desired and should not be placed too close to the limbus or in contact 
with the wound edges. After all the sponges have been removed, the site is irrigated with 
copious amounts of saline solution to remove residual antifibrotic agents.  
Although anti-mitotic agents improved the success rate of trabeculectomy (Chen et al, 
1990;Kitazawa et al, 1991), there is an increased risk of early postoperative complications 
such as hypotony, bleb rupture, and infectious endophthalmitis (Shields et al, 1993; 
Greenfield and Parrish, 1996; Singh et al, 2000; WuDunn et al, 2002; Palanca-Capistrano et al, 
2009). Another common late complication is bleb leakage, which may cause other serious 
complications such as infection, hypotony related maculopathy, and corneal endothelial 
decompensation (Greenfield et al, 1996; Nuyts et al, 1994). Thus, understanding, 
mechanisms of wound healing following MMC treatment is important to reduce bleb-
related complications of leakage.   
As a mechanism of MMC action, it is commonly accepted that inhibiting fibroblast 
proliferation leads to decreased conjunctival adhesion and maintaining the bleb (Lama and 
Fechtner, 2003). In terms of the pharmacokinetics of MMC, the t1/2 in blood doses of 30, 20, 
and 10 (mg/body) is 50, 43, and 10 minutes, respectively (Fujita, 1982). This suggests that 
the half-life of MMC is very short. Because we use MMC at a dosage of less than 1% on the 
sclera for several minutes in trabeculectomy, its effective lifespan seems to be less than 
several hours. As stated above, fibroblasts appear and are activated at 12 hours after surgery 
by macrophages and various cytokines that are released from T-cells. Therefore, it seems 
unreasonable that MMC directly suppresses fibroblasts’ proliferation.  
It is more likely that MMC initially suppresses the proliferation of mast cells, including 
chymase-positive cells which may promote inflammatory response. As a result of this, 
fibroblast proliferation is then restrained (Okada et al, 2009).  In fact, topical instillation of an 
anti-mast-cell agent, tranilast, was useful for filtering bleb formation and IOP  
reduction (Chihara et al, 2002). Therefore, suppression of mast cells might be related to 
formation of the filtering bleb. In addition, chymase inhibition might play a role in 
maintaining filtering blebs for an extended period of time. It has been reported that a 
chymase inhibitor prevents adhesion for up to three months in an abdomen adhesion model 
(Okamoto et al, 2004), so bleb formation may be maintained for a long period if MMC 
inhibits chymase function after tissue injury. Further investigation is needed to verify that 
chymase inhibitors are appropriate for glaucoma surgeries.    
5.3 Anti-vascular endothelial growth factor (VEGF) antibodies 
Pathologic angiogenesis is frequently associated with massive inflammation and migration 
of fibroblasts. It was shown that cultured conjunctival fibroblasts could be stimulated to 
produce VEGF by pro inflammatory cytokines (sano-Kato et al, 2005), and Tenon’s capsule 
fibroblasts were inhibited by angiogenesis inhibitors (Wong et al, 1994). Based on these 
findings, it is imaginable that a selective inhibition of growth factors such as VEGF could be 
an approach to prevent or treat extensive wound healing. To further elucidate the direct 
effect of anti-VEGF agents on fibroblasts, Guerriero et al. illustrated in vitro effects of 
bevacizumab on human corneal and conjunctival fibroblast cell lines. Their research 
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concluded that when corneal stromal fibroblasts are exposed to bevacizumab, loss of cell-to-
cell adhesions and morphological changes are seen. They further stated that these changes 
are dose-dependent (Guerriero et al. 2006). 
Currently, two therapeutic anti-VEGF antibodies exist; bevacizumab and ranibizumab. The 
use of subconjunctival bevacizumab 1mg in 0.04ml to treat a failing filtering bleb in addition 
to a needling procedure has been described in one patient (Kahook et al, 2006b). This patient 
showed an immediate decrease in IOP and was symptomatically improved as well. 
Bevacizumab has also been used in neovascular glaucoma (Kahook et al, 2006a; Michels et 
al, 2005). Kapetansky et al. studied the utility of subconjunctival bevacizumab injections 
administered proximal to blebs after trabeculectomy at the earliest sign of vascularization 
(Kapetansky et al, 2007). They noted that nearly two thirds of the blebs had an observable 
reduction in vascularity while decreasing IOP from a mean of 17.8 to 14mmHg 1 month 
after injection. Improved results were noted when the injections were given earlier in the 
postoperative phase. Coote et al presented a case of subconjunctival injection of 
bevacizumab that resulted in a dramatic reduction of bleb vascularity for 6 weeks. In their 
case, even 6 months after injection, a healthy bleb with minimal scar tissue was seen (Coote 
et al., 2008). 
Ranibizumab is a fully humanized monoclonal antibody-fragment and therefore has a low 
molecular weight, which results in good tissue penetration. The antibody deactivates all 
isoforms of VEGF-A.  Although intraocular injection of the drug showed no toxic side effects 
in an animal model (Manzano et al, 2006), the disadvantage of this form of application in 
trabeculectomy is the short half life of the drug. Although ranibizumab has a longer 
intravitreal half-life (6 days), this form of application does not cover the main peak of 
scarring reaction that is occurring around 2-3 weeks after surgery (Choi et al, 2010).  For 
example, Purcell et al. noted decreased IOP and bleb vascularization after bleb needle 
revision using ranibizumab. But, this effect was short-lived, as increased vascularization 
was noted after 1 month of follow-up (Purcell, et al. 2008). 
Further studies are needed to better understand how anti-VEGF agents might benefit 
patients undergoing glaucoma filtration surgery. There are ongoing safety studies to better 
analyze the importance of route of administration – intracameral, sub-Tenon and intravitreal 
– and to determine whether unknown side effects co-exist. It is important to delineate 
duration of action when anti-VEGF agents are injected in the intra or sub-Tenon’s space and 
how this might influence efficacy. 
6. Amniotic membrane as a modulator of trabeculectomy wound healing  
6.1 Fetal strategy of wound healing 
The amniotic membrane shares the same cell origin as the fetus. The majority of the studies 
testify the clinical efficacy of amniotic membrane transplantation (AMT) in gearing adult 
wound healing toward regeneration with minimal inflammation and scarring, suggesting 
that amniotic membrane (AM), like the fetal tissue, carries similar features that may not only 
facilitate regeneration but also inhibit scar formation  (Mast et al, 1992; Adzick and Lorenz, 
1994) 
A number of mechanisms have been put forth to explain the AM’s biological actions in 
modulating adult wound healing toward the fetal direction with anti-inflammation, anti-
scarring and anti-angiogenesis. (Tseng et al, 2004).  
It remains unclear whether such therapeutic actions are directly or indirectly linked to 
modulate healing and differentiation. AM has been shown to down-regulate transforming 
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growth factor-β signaling in cultured normal conjunctival fibroblasts (Tseng et al., 1999; Lee 
et al., 2000) and to inhibit the cellular migration triggered by vascular endothelial growth 
factor (VEGF) (Shey et al., 2011).  Furthermore, AM can exert potent anti-inflammatory 
effects by facilitating macrophage apoptosis (Li et al, 2006).   
6.2 Preliminary studies 
Several investigators have explored the clinical efficacy of deploying AM as an adjunctive 
therapy to improve the surgical outcome of various glaucoma procedures, including 
trabeculectomy (Sheha et al, 2010). They have shown that transplantation of a single 
(Fujishima et al, 1998; Lu and Mai, 2003; Yue et al, 2003; Drolsum et al, 2006) or folded 
(Bruno et al, 2006; Eliezer et al, 2006) sheet of AM under the scleral flap (Fujishima et al, 
1998; Yue et al, 2003; Drolsum et al, 2006; Bruno et al, 2006), and/or under the conjunctiva 
(Yue et al, 2003; Drolsum et al, 2006; Bruno et al, 2006; Eliezer et al, 2006), with additional 
MMC (Fujishima et al, 1998; Drolsum et al, 2006; Bruno et al, 2006), reduces IOP in eyes with 
refractory glaucoma. Experimental rabbit studies demonstrated that the AM, inserted under 
the scleral flap, achieves the same reduction of subconjunctival fibroblasts and macrophages 
around the trabeculectomy sites as that achieved by MMC (Demir et al, 2002; Wang et al, 
2005), as well as reduces the number of fibroblasts at trabeculectomy sites when inserted 
under the scleral flap even without MMC (Zhong et al, 2000; Barton et al, 2001).  
6.3 Potential advantages of AM 
We have conducted the first prospective randomized trial to demonstrate the clinical 
efficacy of transplanting a single layer of cryopreserved AM under and around the scleral 
flap (Fig. 3), in conjunction with application of MMC in refractory glaucoma. In this study of 
37 eyes, 18 received 0.2 mg/ml MMC under the flap for 2 min while 19 received additional 
implantation of cryopreserved AM under and around the scleral flap (Sheha et al, 2008). 
 
 
Fig. 3. AMT in trabeculectomy. AM (1) inserted under and around the scleral flap (2) 
In the control MMC only group, IOP continuously rose between 3 and 12 months 
postoperatively. The incidence of encapsulated blebs, which are caused by collagen-
producing fibroblasts (Ophir, 1992), was greater in the control group (38.9% vs. 5.3%) at 12 
months postoperatively. This indicates that the effect of MMC was not sufficient to suppress 
scar formation, potentially due to its short half-life. 
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At 12 months postoperatively, the group with AM transplantation achieved significantly 
higher rates of complete (IOP ≤ 21 mmHg without medications) and qualified success (IOP ≤ 
21 mmHg with or without additional medications). Furthermore, the resultant blebs were 
diffuse and translucent, but still retained normal vascularity (Fig. 4A). This bleb morphology 
was notably different from a MMC-induced ischemic bleb, which is prone to develop late 
complications such as bleb leak and infection (Fig. 4B). There were significantly fewer early 
postoperative complications such as shallow anterior chamber and choroidal effusion. These 
beneficial effects may be attributed to the fact that AM inserted under the scleral flap 
effectively halts rapid drainage of aqueous humor from the trabeculectomy site to reduce 
immediate hypotony from overfiltration and reduces scarring in the filtration site in the long 
run.  
Hence, it is plausible that AM implanted in subconjunctival and subscleral spaces might 
reduce the adverse side effects intrinsically associated with MMC and with over-filtration, 
making AM a unique natural biological modulator that may exert a similar anti-scarring action 
to MMC while eliminating the potential sight-threatening complications known to MMC. 
 
  
Fig. 4. Comparison between functioning bleb with normal vascularity after AMT (A) and 
ischemic leaking bleb after MMC (B); arrow indicates the bleb leak revealed by fluorescein 
staining (B) 
The aforementioned favorable results could be attributed to a synergistic beneficial effect of 
MMC and AM on controlling fibrosis at the trabeculectomy site. It remains unclear whether 
the AM can substitute MMC completely in trabeculectomy. Furthermore, the mechanism 
through which the AM exerts its effects as well as its fate in the subscleral space over time 
remains largely unknown. The AM may not only prevent scar formation via its known anti-
inflammatory and anti-scarring actions but may also serve as a spacer integrated into the 
internal bleb structure to stabilize the patency of the filtering fistula and maintain a 
functioning bleb.  
Currently we are studying the fate of AM and internal bleb morphology. Although 
histological studies showed that human AM dissolves at 1 month postoperatively in rabbits 
(Wang et al, 2005), we do not know whether similar AM dissolution also occurred in human 
patients. We have gathered preliminary data supporting the feasibility of using anterior 
segment optic coherence tomography (OCT) to detect the presence of AM and the evidence 
of host cell integration into the AM after being transplanted in the subconjunctival space to 
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cover the glaucoma shunt tube. Our results showed that implanted AM maintained its 
thickness over a period of 12 months (Anand et al, 2011). 
6.4 Evidence of AM anti-angiogenic action  
Pathologic angiogenesis that is frequently associated with uncontrolled inflammation may 
lead to fibrosis. While reducing fibrosis in subconjunctival and subscleral spaces as shown 
above, AM was found to deliver anti-angiogenic actions to resolve rubeosis iridis that is 
known to occur in neovascular glaucoma. In our study, there were 7 eyes with neovascular 
glaucoma in each group, which was accompanied by circumcorneal congestion, 
neovascularization at the angle and the iris in the form of rubeosis iridis (Fig. 5A), and 
hyphema (Fig. 6A). Interestingly, 2 weeks following implantation of AM, we observed rapid 
resolution of the circumcorneal congestion and dramatic regression of the anterior chamber 
neovascularization (Fig. 5B) and hyphema (Fig. 6B). The effect was persistent through 12 
months of follow-up. 
 
  
Fig. 5. Resolution of rubeosis iridis (arrows) in neovascular glaucoma 
Hence, our study was the first showing AM’s anti-angiogenic clinical efficacy. Because such 
an action was not associated with reduction of the normal vascularity of the bleb (Fig.4A), 
we speculate that AM’s anti-angiogenic action is preferentially directed toward abnormal 
neovascularization. This novel therapeutic action against neovascularization may add an 
extra benefit in the management of high-risk neovascular glaucoma.  
 
  
Fig. 6. Rapid resolution of rubeosis iridis (white arrow) and hyphema (green arrow) in 
neovascular glaucoma 
www.intechopen.com
 
Update on Modulating Wound Healing in Trabeculectomy 
 
411 
7. Future research 
Our preliminary studies designate that the implantation of AM to lower IOP in 
trabeculectomy represents a significant advance in treating glaucoma by eliminating 
complications associated with MMC and over-filtration. Further understanding of the fate 
of AM via imaging studies will not only confirm its anti-inflammatory and anti-scarring 
effects but will also teach us how intrableb wound healing can be modulated by the AM 
regarding integration into the surrounding operated tissue. Such knowledge will further 
strengthen our belief that AM can be a natural biological matrix derived from the fetus that 
may modulate adult wound healing toward regeneration through the reduction of 
inflammation, scarring, and unwanted new blood vessel formation. Further proof of the 
anti-angiogenic action of AM in reverting neovascularization in cases of neovascular 
glaucoma will generate a direct impact on using AM to treat ocular diseases where 
angiogenesis threatens vision. We expect that such a treatment will be more effective than 
the conventional approach based on an antibody blockade against VEGF, because AM not 
only suppresses angiogenesis mediated by VEGF and other growth factors, but also 
curtails inflammation and scarring. This innovative concept can then be applied to other 
parts of the body where pathological fibrosis or angiogenesis is considered detrimental and 
undesirable.  
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